Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biomarker Predicts Chemo Response for Osteosarcoma

Published: Wednesday, July 04, 2012
Last Updated: Wednesday, July 04, 2012
Bookmark and Share
Scientists have found that a protein expressed by some cancers is a good predictor of how the cancer will respond to standard chemotherapy.

Knowing whether a patient's tumor has this protein biomarker could help doctors determine if a patient should undergo standard treatment or if a more aggressive or alternative therapy may be more effective.

"This is the first time that a biomarker has been identified that predicts treatment success for osteosarcoma," said Dariusz Borys, assistant professor in the UC Davis Department of Pathology and Laboratory Medicine and lead author of the study. "It is a first step in individualizing therapy to maximize success based on a protein that the cancer expresses."

Osteosarcoma is usually diagnosed during the teenage years. It also may affect people over 60.

Osteosarcoma is typically treated with "neoadjuvant therapy," which involves several cycles of chemotherapy using a combination of drugs to shrink the tumor before it is surgically removed. How effective the chemotherapy is in inducing cancer cell death (necrosis) is the best predictor of a patient's survival following surgery. But a tumor's response to chemotherapy varies widely among patients and, until now, a way to predict whether the chemotherapy will work well has not been identified.

The investigators focused on a protein expressed by cancer cells known as P16, which inhibits cell growth. For unknown reasons, some cancers stop expressing P16. The researchers found that patients who had cancers that still expressed P16 were more likely to respond well to chemotherapy.
"It is useful to know ahead of time if patients are likely to respond to standard therapy," said Borys. "Those who have tumors that do not express P16 would be especially good candidates for more aggressive or experimental treatments to see if they might respond better."

The study enrolled 40 patients, aged 9 to 75 years old (median age, 15 years), with osteosarcoma at UC Davis and UC San Francisco. Pathologic specimens of the tumors before treatment were collected for study from each patient and were analyzed for P16 expression. After chemotherapy, during surgery to remove the tumor, specimens were again collected and analyzed for the extent of tumor cell death. A little more than half of the patients responded well to chemotherapy, and these patients were found to be significantly more likely to have had tumors that expressed the P16 protein.

Data on how the patients fared clinically were not available for this study, but it has been well established from other studies that the amount of tumor killed preoperatively is strongly associated with survival.

Borys said more patients will be studied to strengthen the findings, and on a molecular level, more study is needed to clarify why some cancer cells stop expressing P16.

The study was a collaboration among three institutions on the West Coast (UC Davis, UC San Francisco and University of Washington) and involved pathologists and surgeons. According to Borys, pathologists traditionally have been used to help establish a diagnosis, but are now moving toward an equally important role in helping clinicians determine treatment strategies.

"Pathologists will one day be able to provide answers to better help clinicians cure their patients," said Borys. "Our work to improve the treatment of osteosarcoma is an important step in that direction."
The article is titled, "P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy."

Other UC Davis study authors were Robert J. Canter and Steve R. Martinez, surgical oncologists at the Comprehensive Cancer Center, Robert M. Tamurian of the Department of Orthopedic Surgery, John Bishop of the Department of Pathology and Laboratory Medicine and Brian Murphy of the Veterinary School's Department of Pathology. Andrew Horvai of the UC San Francisco Medical Center was co-principal investigator with Borys. Benjamin Hoch of the University of Washington was another study author.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Simple Technology Makes CRISPR Gene Editing Cheaper
University of California, Berkeley, researchers have discovered a much cheaper and easier way to target a hot new gene editing tool, CRISPR-Cas9, to cut or label DNA.
Friday, July 24, 2015
Delivering Drugs to the Right Place
Thomas Weimbs has developed a targeted drug delivery method that could potentially slow the progression of polycystic kidney disease.
Monday, June 29, 2015
Designing New Pain Relief Drugs
Researchers have identified the molecular interactions that allow capsaicin to activate the body’s primary receptor for sensing heat and pain, paving the way for the design of more selective and effective drugs to relieve pain.
Thursday, June 11, 2015
Engineers Crack DNA Code of Autoimmune Disorders
Researchers have identified an unexpectedly general set of rules that determine which molecules can cause the immune system to become vulnerable to the autoimmune disorders lupus and psoriasis.
Wednesday, June 10, 2015
Genetic Markers for Detecting and Treating Ovarian Cancer
Custom bioinformatics algorithm identifies human mRNAs that distinguish ovarian cancer cells from normal cells and provide new therapeutic targets
Wednesday, May 27, 2015
Industry-Sponsored Academic Inventions Spur Increased Innovation
Analysis questions assumption that corporate support skews science toward inventions that are less useful than those funded by the government or non-profit organizations.
Monday, March 24, 2014
Chemical Signature for Fast Form of Parkinson's Found
The physical decline experienced by Parkinson's disease patients eventually leads to disability and a lower quality of life.
Monday, November 25, 2013
Digging Deeper Into Cancer
What a pathologist looks for in a Pap test sample, but hopes not to find, are oddly shaped cells with abnormally large nuclei. The same is true for prostate and lung cancer biopsies.
Tuesday, November 19, 2013
Discovery Could Lead to Saliva Test for Pancreatic Cancer
The disease is typically diagnosed through an invasive and complicated biopsy.
Tuesday, October 15, 2013
Biologists Find New Method for Discovering Antibiotics
Biologists have developed a revolutionary new method for identifying and characterizing antibiotics.
Tuesday, September 17, 2013
Potential Drug Discovered for Severe Form of Epilepsy
UCSF study found effectiveness of antihistamine on zebrafish bred to mimic disease.
Thursday, September 05, 2013
Potential New Drug for Inflammatory Bowel Disease
Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis.
Monday, September 02, 2013
Dentistry School Receives $5M to Study Saliva Biomarkers
Imagine having a sample of your saliva taken at the dentist's office, and then learning within minutes whether your risk for stomach cancer is higher than normal.
Thursday, August 15, 2013
Brain Anomolies are Potential Biomarkers for Autism
Brain anomalies may serve as potential biomarkers for the early identification of the neurodevelopmental disorder.
Wednesday, July 10, 2013
Second Amyloid May Play a Role in Alzheimer's
The study is the first to identify deposits of the protein, called amylin, in the brains of people with Alzheimer's disease.
Monday, July 01, 2013
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
Crystal Clear Images Uncover Secrets of Hormone Receptors
NIH researchers gain better understanding of how neuropeptide hormones trigger chemical reactions in cells.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!